S Samuel Kim1, Jennifer Klemp, Carol Fabian. 1. Division of Reproductive Endocrinology and Infertility, University of Kansas School of Medicine, Kansas City, Kansas, USA. skim2@kumc.edu
Abstract
OBJECTIVE: To review the benefits of adjuvant systemic therapy given to women with breast cancer of reproductive age, its effects on fertility, and options for fertility preservation. DESIGN: Publications relevant to fertility preservation and breast cancer were identified through a PubMed database search. CONCLUSION(S): Most women who develop invasive breast cancer under age 40 will be advised to undergo adjuvant chemotherapy with or without extended antihormonal therapy to reduce the risk of recurrence and death from breast cancer. Adjuvant chemotherapy particularly with alkylating agents such as cyclophosphamide is gonadotoxic and markedly accelerates the rate of age-related ovarian follicle loss. Although loss of fertility is an important issue for young cancer survivors, there is often little discussion about fertility preservation before initiation of adjuvant therapy. Greater familiarity with prognosis and effects of different types of adjuvant therapy on the part of infertility specialists and fertility preservation options such cryopreservation of embryos, oocytes, and ovarian tissue on the part of oncologists would facilitate these discussions. Establishment of rapid fertility consultation links within cancer survivorship programs can help ensure that every young woman who is likely to undergo gonadotoxic cancer treatment is counseled about the effects of therapy and options available to her to increase the likelihood of childbearing after cancer treatment.
OBJECTIVE: To review the benefits of adjuvant systemic therapy given to women with breast cancer of reproductive age, its effects on fertility, and options for fertility preservation. DESIGN: Publications relevant to fertility preservation and breast cancer were identified through a PubMed database search. CONCLUSION(S): Most women who develop invasive breast cancer under age 40 will be advised to undergo adjuvant chemotherapy with or without extended antihormonal therapy to reduce the risk of recurrence and death from breast cancer. Adjuvant chemotherapy particularly with alkylating agents such as cyclophosphamide is gonadotoxic and markedly accelerates the rate of age-related ovarian follicle loss. Although loss of fertility is an important issue for young cancer survivors, there is often little discussion about fertility preservation before initiation of adjuvant therapy. Greater familiarity with prognosis and effects of different types of adjuvant therapy on the part of infertility specialists and fertility preservation options such cryopreservation of embryos, oocytes, and ovarian tissue on the part of oncologists would facilitate these discussions. Establishment of rapid fertility consultation links within cancer survivorship programs can help ensure that every young woman who is likely to undergo gonadotoxic cancer treatment is counseled about the effects of therapy and options available to her to increase the likelihood of childbearing after cancer treatment.
Authors: Kelly-Anne Phillips; Richard H Osborne; Graham G Giles; Gillian S Dite; Carmel Apicella; John L Hopper; Roger L Milne Journal: J Clin Oncol Date: 2008-10-01 Impact factor: 44.544
Authors: Abenaa M Brewster; Gabriel N Hortobagyi; Kristine R Broglio; Shu-Wan Kau; Cesar A Santa-Maria; Banu Arun; Aman U Buzdar; Daniel J Booser; Vincente Valero; Melissa Bondy; Francisco J Esteva Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: E L Milliken; K L Lozada; E Johnson; M D Landis; D D Seachrist; I Whitten; A L M Sutton; F W Abdul-Karim; R A Keri Journal: Oncogene Date: 2007-09-24 Impact factor: 9.867
Authors: Joseph A Sparano; Molin Wang; Silvana Martino; Vicky Jones; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson Journal: N Engl J Med Date: 2008-04-17 Impact factor: 91.245
Authors: Claus Yding Andersen; Mikkel Rosendahl; Anne Grete Byskov; Anne Loft; Christian Ottosen; Margit Dueholm; Kirsten L T Schmidt; Anders Nyboe Andersen; Erik Ernst Journal: Hum Reprod Date: 2008-07-03 Impact factor: 6.918
Authors: Martine Berliere; Florence Dalenc; Nathalie Malingret; Anita Vindevogel; Philippe Piette; Henry Roche; Jacques Donnez; Michel Symann; Joseph Kerger; Jean-Pascal Machiels Journal: BMC Cancer Date: 2008-02-21 Impact factor: 4.430
Authors: Susan T Vadaparampil; Juliette Christie; Gwendolyn P Quinn; Patrice Fleming; Caitlin Stowe; Bethanne Bower; Tuya Pal Journal: Support Care Cancer Date: 2012-01-24 Impact factor: 3.603
Authors: F Cavagna; A Pontes; M Cavagna; A Dzik; N F Donadio; R Portela; M T Nagai; L H Gebrim Journal: Curr Oncol Date: 2018-12-01 Impact factor: 3.677
Authors: K Kyono; T Hashimoto; M Toya; M Koizumi; C Sasaki; S Shibasaki; N Aono; Y Nakamura; R Obata; N Okuyama; Y Ogura; H Igarashi Journal: J Assist Reprod Genet Date: 2017-09-02 Impact factor: 3.412
Authors: Mirjam M Garvelink; Moniek M ter Kuile; Rinske M Bakker; Willemijn J Geense; Esther Jenninga; Leoni A Louwé; Carina G J M Hilders; Anne M Stiggelbout Journal: Health Expect Date: 2013-05-05 Impact factor: 3.377